Suggested remit: To appraise the clinical and cost effectiveness of nivolumab with chemotherapy and nivolumab monotherapy within its marketing authorisation for neoadjuvant and adjuvant treatment of resectable non-small-cell lung cancer (NSCLC).
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- Cost Comparison Standard
- ID number:
- 6310
Provisional Schedule
- Expected publication:
- 17 December 2025
Project Team
- Project lead
- Kate Moore
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- Liverpool Reviews and Implementation Group, University of Liverpool
Stakeholders
- Companies sponsors
- Bristol Myers Squibb (nivolumab)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- None
- Professional groups
- Association of Cancer Physicians
- British Thoracic Oncology Group
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- Associated public health groups
- None
- Comparator companies
- AstraZeneca (durvalumab) - confidentiality agreement signed, participating
- Eli Lilly (pemetrexed) - confidentiality agreement signed, participating
- Pfizer (cisplatin, carboplatin, docetaxel, oxaliplatin, paclitaxel, pemetrexed) - confidentiality agreement signed, participating
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health – Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 20 March 2025 | Invitation to participate |
| 10 February 2025 | Invitation to participate |
| 13 January 2025 - 27 January 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 21 June 2024 | Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the [appraisal is now anticipated to begin during early February 2025 when we will write to you about how you can get involved. |
| 31 May 2024 | Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course. In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes. |
| 16 January 2024 - 13 February 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6310 |
| 15 September 2023 | Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-April 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-June 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
| 03 July 2023 | In progress |
| 23 November 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual